GlassScriptPhysician profile
Calvin Mark Newton
NPI 1205857653
$18,558.29
in general payments reported to CMS, 2019-2025
44 companies · $1,201 in 2025
The $1,201 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,808 · 2020: $6,049 · 2021: $1,151 · 2022: $1,351 · 2023: $1,482 · 2024: $4,517 · 2025: $1,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,927 · Travel and Lodging: $1,703 · Consulting Fee: $1,500 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,927.07 |
| Travel and Lodging | $1,702.72 |
| Consulting Fee | $1,500.00 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $5,070.90 | 2019-2020 | |
| Bard Peripheral Vascular, INC. | $4,022.23 | 2021-2024 | Venclose Maven Catheter |
| Medtronic Vascular, INC. | $1,399.71 | 2019 | |
| Abbott Laboratories | $836.51 | 2020-2025 | Coroflow, Thoratec Heartmate 3 Lvas Implant Kit, Optis |
| Novartis Pharmaceuticals Corporation | $742.86 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $733.22 | 2019-2025 | Farxiga, Lokelma, Wainua |
| Abiomed | $667.19 | 2019-2025 | |
| Medtronic, INC. | $530.75 | 2021-2025 | Abre, Closurefast, Venaseal |
| Pfizer INC. | $493.37 | 2019-2025 | |
| Amgen INC. | $403.56 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $365.57 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $312.81 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $307.33 | 2022-2025 | Watchman Flx, Varithena Administration Pack |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $282.11 | 2019-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $264.20 | 2023-2025 | Onpattro |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calvin Newton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.